Start-Up Quarterly Statistics, Q4 2012
This article was originally published in Start Up
Start-ups raised a total of $670.3 million across all industries in Q4 2012, just $11.6 million less than in Q3, and 90% of that money went to biopharma companies. Several start-up companies inked deals with Big Pharmas, and there were three acquisitions – two in biopharma and one in the device sector.
You may also be interested in...
The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.
Ultragenyx raised $75 million in a Series B financing led by Adage Capital Partners. The funding will support the biotech’s two lead programs that are meant to treat ultra-rare genetic disorders and will position the company for an initial public offering.
Bristol-Myers Squibb has agreed to license its already-marketed topical hemostat to The Medicines Company for $115 million upfront and royalties. The agreement will last for two years and add to The Medicines Co.'s portfolio of perioperative care products.